Novocure (NASDAQ:NVCR) announced today that it has sponsored Pulitzer Prize-winning author Dr. Siddhartha Mukherjee as the keynote speaker of the 21 st Annual Scientific Meeting of the Society for Neuro-Oncology on Nov. 19, 2016, in Scottsdale, Arizona. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161114005480/en/
Novocure has sponsored Pulitzer Prize-winning author Dr. Siddhartha Mukherjee as the keynote speaker of 21st Annual Scientific Meeting of the Society for Neuro-Oncology on Nov. 19, 2016, in Scottsdale, Arizona. (Photo: Business Wire)"I am deeply honored to deliver a talk at the Society for Neuro-Oncology meeting," Dr. Mukherjee said. "The prevention, treatment and cure of brain cancers remain a major scientific challenge, although new medical breakthroughs are changing the landscape for patients. The society's meeting will highlight these important breakthroughs and focus attention on these important cancers." Dr. Mukherjee, a physician and researcher, wrote the Pulitzer Prize-winning and New York Times bestselling book The Emperor of All Maladies, a biography of cancer, which chronicles the disease. In 2015, PBS premiered a documentary from Ken Burns based on Dr. Mukherjee's book. Dr. Mukherjee's follow-up, bestselling book, The Gene: An Intimate History - published in 2016 - tells "the story of the quest to decipher the master-code of instructions that makes and defines humans, that governs our form, function, and fate and determines the future of our children." "We are honored to support Dr. Mukherjee's keynote address during the SNO annual meeting and commend his important work as a cancer researcher, physician and author who has educated many on the story of cancer," said Bill Doyle, Novocure's Executive Chairman. "We believe Novocure is an innovator in cancer treatment and an important contributor to the evolution of cancer care moving forward."
About NovocureNovocure is a commercial-stage oncology company developing a novel, proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. Novocure's commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed phase 2 pilot trials investigating TTFields in NSCLC, pancreatic cancer, ovarian cancer and mesothelioma. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Haifa, Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure. Forward-Looking Statements In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Novocure's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on March 1, 2016, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.